Press release

Chiesi Group Selects IQVIA’s OCE Technology Platform to Develop a Customer Centric Ecosystem across the Organization

Sponsored by Businesswire

(NYSE:IQV) today announced that Chiesi Farmaceutici, the international
research-focused healthcare Group (Chiesi Group) is leveraging IQVIA
Technologies’ Orchestrated
Customer Engagement (OCE)
technology platform to enhance customer
proximity and teamwork effectiveness in more than 20 markets, including
the U.S., China, Germany, U.K., France, Spain, Italy, Russia and Brazil.

“Working with IQVIA, we are able to provide a customer-centric approach
and leverage their deep industry expertise and robust technology
ecosystem,” said Ugo Di Francesco, Chief Executive Officer of Chiesi
Group. “Chiesi is committed to innovation in all that we do, and it was
critical for us to partner with a global vendor who shares this value.
Our multi-national environment is complex, and OCE has the
sophistication to meet the needs of our different commercial teams and
their unique customers — today and in the future.”

IQVIA Technologies’ OCE is a new category of cloud-based life sciences
technology built on the latest best-in-class platforms, including
Salesforce, Amazon, Box, Heroku and Mulesoft. The OCE platform enables
companies to move from a patchwork of point applications to a unified
commercial solution that evolves with technical and business

“We are proud to facilitate the evolution of Chiesi’s commercial model
and support its goal to deliver exceptional customer experiences to a
diverse audience of HCPs around the world,” said Tal Rosenberg, senior
vice president of Global Technology Solutions for IQVIA. “OCE is a
transformative technology platform that connects sales, marketing,
medical and other customer-facing functions. By harmonizing multichannel
interactions, it not only optimizes commercial team performance but also
fosters customer trust and loyalty.”

Chiesi will achieve its globally connected commercial ecosystem using
OCE Sales, OCE Marketing and IQVIA’s OneKey healthcare professionals’
database. These tools will empower Chiesi to develop personalized
multichannel sales journeys for targeted customers and track
effectiveness with visual tools. Other features include content
marketing management, campaign management, account and contact
management, segmentation, field model optimization and interaction

For more information about IQVIA Technologies, OCE and OneKey, please


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 58,000
employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
information on a scale that helps healthcare stakeholders identify
disease patterns and correlate with the precise treatment path and
therapy needed for better outcomes. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical companies,
medical researchers, government agencies, payers and other healthcare
stakeholders tap into a deeper understanding of diseases, human
behaviors and scientific advances, in an effort to advance their path
toward cures. To learn more, visit

About Chiesi Group

Based in Parma, Italy, Chiesi Farmaceutici is an international
research-oriented group with over 80 years’ experience in the
pharmaceutical sector and is present in 27 countries. The group
researches, develops and commercializes innovative medicines in the
respiratory disease, special care and rare disease therapeutic areas.
The Group’s Research & Development center is based in Parma (Italy) and
integrated with 6 other important research and development groups in
France, the USA, the UK and Sweden to promote its pre-clinical, clinical
and registration programs. The Group employs around 5,700 people. Chiesi
Group is a certified B Corporation. For more information, please visit


here to subscribe to Mobile Alerts for IQVIA